ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer

Breast cancer is one of the most common cancers in humans. However, our understanding of the cellular and molecular mechanisms underlying tumorigenesis in breast tissues is limited. Here, we identified a molecular mechanism that controls the ability of breast cancer cells to form multicellular spheroids (mammospheres). We found that heregulin (HRG), a ligand for ErbB3, induced mammosphere formation of a breast cancer stem cell (BCSC)–enriched population as well as in breast cancer cell lines. HRG-induced mammosphere formation was reduced by treatment with inhibitors for phosphatidyl inositol 3-kinase (PI3K) or NF-κB and by expression of IκBα-Super Repressor (IκBαSR), a dominant-negative inhibitor for NF-κB. Moreover, the overexpression of IκBαSR in breast cancer cells inhibited tumorigenesis in NOD/SCID mice. Furthermore, we found that the expression of IL8, a regulator of self-renewal in BCSC-enriched populations, was induced by HRG through the activation of the PI3K/NF-κB pathway. These findings illustrate that HRG/ErbB3 signaling appears to maintain mammosphere formation through a PI3K/NF-κB pathway in human breast cancer.

[1]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[2]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[3]  K. Eguchi,et al.  DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. , 2006, International journal of oncology.

[4]  M. Wicha,et al.  HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion , 2008, Oncogene.

[5]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[7]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H Aburatani,et al.  Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells , 2009, British Journal of Cancer.

[9]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[10]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[11]  W. Gullick,et al.  The Neuregulin Family of Genes and their Multiple Splice Variants in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[12]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[13]  N. Gotoh,et al.  Inflammatory signaling pathways in self-renewing breast cancer stem cells. , 2010, Current opinion in pharmacology.

[14]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[15]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[16]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[17]  P. Leder,et al.  NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. , 1996, Oncogene.

[18]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[19]  M. Wicha.  Targeting breast cancer stem cells. , 2009, Breast.

[20]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[21]  Irving L. Weissman,et al.  Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 , 2011, Nature.

[22]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[23]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[24]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[25]  R. Lupu,et al.  Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. , 2003, Molecular cancer research : MCR.

[26]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[27]  C. Stove,et al.  Roles for neuregulins in human cancer , 2005, Clinical & Experimental Metastasis.

[28]  N. Gotoh.  Potential Signaling Pathways Activated in Cancer Stem Cells in Breast Cancer , 2011 .

[29]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.

[30]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[31]  S. Lakhani,et al.  Breast cancer stem cells: implications for therapy of breast cancer , 2008, Breast Cancer Research.

[32]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[33]  J. Menéndez,et al.  Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[35]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[36]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[37]  Chiou-Feng Lin,et al.  Anesthetic Propofol Reduces Endotoxic Inflammation by Inhibiting Reactive Oxygen Species-regulated Akt/IKKβ/NF-κB Signaling , 2011, PloS one.

[38]  Sophia Hsin-Jung Li,et al.  Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast , 2011, Cell.

[39]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[40]  William J Gullick,et al.  Co‐expression of neuregulins 1, 2, 3 and 4 in human breast cancer , 2004, The Journal of pathology.

[41]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.